Predictive Value of Plasma NGAL:Hepcidin-25 for Major Adverse Kidney Events After Cardiac Surgery with Cardiopulmonary Bypass: A Pilot Study
Christian Albert, Michael Haase, Annemarie Albert, Martin Ernst, Siegfried Kropf, Rinaldo Bellomo, Sabine Westphal, Ruediger C. Braun‐Dullaeus, Anja Haase‐Fielitz, Saban Elitok
Abstract
BACKGROUND: Neutrophil gelatinase-associated lipocalin (NGAL) and hepcidin-25 are involved in catalytic iron-related kidney injury after cardiac surgery with cardiopulmonary bypass. We explored the predictive value of plasma NGAL, plasma hepcidin-25, and the plasma NGAL:hepcidin-25 ratio for major adverse kidney events (MAKE) after cardiac surgery. METHODS: We compared the predictive value of plasma NGAL, hepcidin-25, and plasma NGAL:hepcidin-25 with that of serum creatinine (Cr) and urinary output and protein for primary-endpoint MAKE (acute kidney injury [AKI] stages 2 and 3, persistent AKI >48 hours, acute dialysis, and in-hospital mortality) and secondary-endpoint AKI in 100 cardiac surgery patients at intensive care unit (ICU) admission. We performed ROC curve, logistic regression, and reclassification analyses. RESULTS: =0.014). CONCLUSIONS: Plasma NGAL:hepcidin-25 is a promising marker for predicting postoperative MAKE.